not tagged
not tagged
['solid tumor']
an exciting trial in progress, led by dana-farber's ben schlechter, md ( ). dr. schlechter details this phase i/ii trial looking at safety and efficacy of autologous tac t cells targeting her2 in solid tumors. research presented at #esmo22. 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090